secwatch.observer — SEC 8-K summary
======================================

Issuer:     NRX Pharmaceuticals, Inc. (NRXP)
CIK:        0001719406
Form:       8-K
Filed at:   2024-02-14T23:59:59+00:00
Accession:  0001104659-24-023806
Event type: debt
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NRXP amends $11M convertible note; $1.1M cash due Feb 12, then $400K/month through July
--------------------------------------------------------------------------------

- Third Amendment to $11.02M convertible note with Streeterville Capital executed Feb 9, 2024.
- Company to pay $1.1M cash on Feb 12, 2024; monthly $400K cash minimum from Feb 29 to July 31, 2024.
- During first three months, Streeterville cannot redeem above monthly minimum; after, up to $1M/month subject to cap.
- Company can pay monthly minimum in shares if Streeterville submits redemption notices; otherwise cash required.
- Outstanding balance after July 31, 2024 must be fully paid in cash by Aug 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719406/000110465924023806/0001104659-24-023806-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719406/000110465924023806/tm246184d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-023806

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer